Filgrastim biosimilar - ProfarmaAlternative Names: PF-07
Latest Information Update: 15 Jun 2015
At a glance
- Originator Profarma
- Class Chemoprotectants; Granulocyte colony-stimulating factors; Neuroprotectants
- Mechanism of Action Granulocyte colony stimulating factor stimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 15 Jun 2015 Preclinical trials in Cancer in Lithuania (unspecified route) (Profarma pipeline, June 2015)
- 02 Apr 2015 Profarma has patent protection for filgrastim biosimilar (Profarma website, June 2015) before April 2015